Ali Beyzavi is a scientist with expertise in diagnostics, precision medicine, and in vitro diagnostics (IVD). They led the development of a large dose drug delivery system during a postdoctoral associate position at MIT and later directed R&D for a point-of-care insulin diagnostic assay at OPKO Health. As an independent consultant, Ali contributed to projects on microfluidic technologies for various biotech companies before joining Roche as a scientist and group leader. They are currently focused on the development and commercialization of an innovative FDA-approved next-generation sequencing diagnostic test at Foundation Medicine. Ali holds a Ph.D. in Biomedical Engineering from Boston University and completed postdoctoral training at MIT.
This person is not in the org chart
This person is not in any teams
This person is not in any offices